NPI: 1730182478 · MARSHALL, MO 65340 · General Acute Care Hospital · NPI assigned 05/26/2005
Authorized official HARRIS, NANCY controls 18+ related entities in our dataset. Read more
| Authorized Official | HARRIS, NANCY (CFO/COO) |
| Parent Organization | JOHN FITZGIBBON MEMORIAL HOSPITAL INC. |
| NPI Enumeration Date | 05/26/2005 |
Other providers sharing the same authorized official: HARRIS, NANCY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 6,778 | $1.43M |
| 2019 | 7,342 | $985K |
| 2020 | 7,498 | $341K |
| 2021 | 12,007 | $146K |
| 2022 | 18,244 | $508K |
| 2023 | 20,984 | $728K |
| 2024 | 14,020 | $561K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 13,561 | 12,141 | $1.85M |
| Y7506 | 5,486 | 4,441 | $817K | |
| X4011 | State-specific procedure code | 3,259 | 2,214 | $315K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 2,083 | 1,714 | $300K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 10,427 | 8,052 | $284K |
| 80053 | Comprehensive metabolic panel | 8,797 | 6,789 | $246K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,995 | 1,831 | $161K |
| 87400 | 1,915 | 1,689 | $100K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4,652 | 3,165 | $87K |
| 81003 | 10,568 | 7,340 | $69K | |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 326 | 259 | $68K |
| 87428 | 3,414 | 2,976 | $59K | |
| 71045 | Radiologic examination, chest; single view | 701 | 560 | $34K |
| 36415 | Collection of venous blood by venipuncture | 3,836 | 2,629 | $28K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2,752 | 2,151 | $27K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 389 | 293 | $25K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1,203 | 1,103 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 847 | 606 | $21K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 466 | 382 | $17K |
| 62323 | 124 | 65 | $14K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 129 | 53 | $14K |
| X4006 | 55 | 48 | $13K | |
| 80306 | 972 | 735 | $13K | |
| 87807 | 295 | 285 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | 988 | 830 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 158 | 132 | $11K |
| Y7507 | 100 | 74 | $9K | |
| X4003 | 1,090 | 883 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 671 | 591 | $8K |
| 95819 | 49 | 41 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 280 | 241 | $6K |
| 80061 | Lipid panel | 660 | 551 | $5K |
| 86780 | 394 | 333 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 38 | 14 | $4K |
| 77002 | 75 | 67 | $4K | |
| 87430 | 472 | 436 | $4K | |
| 84439 | 237 | 215 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 351 | 336 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 198 | 175 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | 109 | 77 | $2K |
| 82607 | 256 | 229 | $2K | |
| 83880 | 84 | 55 | $2K | |
| 73110 | 37 | 24 | $2K | |
| 87081 | 406 | 373 | $1K | |
| 84484 | 259 | 178 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 21 | 20 | $876.88 |
| 73610 | 15 | 14 | $819.07 | |
| 84145 | 64 | 54 | $793.60 | |
| 86140 | 433 | 334 | $686.87 | |
| 81025 | 177 | 165 | $682.65 | |
| 96361 | Intravenous infusion, hydration; each additional hour | 31 | 24 | $551.41 |
| 83605 | 139 | 102 | $548.34 | |
| 87070 | 172 | 167 | $514.50 | |
| 85027 | 68 | 55 | $361.23 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 25 | 25 | $221.32 |
| 93041 | 13 | 12 | $171.40 | |
| 82550 | 61 | 54 | $165.80 | |
| 84481 | 19 | 18 | $159.47 | |
| 82077 | 23 | 14 | $131.31 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 15 | 12 | $57.78 |
| 86762 | 15 | 12 | $34.53 | |
| 87340 | 15 | 12 | $24.78 | |
| 86850 | 15 | 12 | $23.43 | |
| J3490 | Unclassified drugs | 137 | 91 | $12.40 |
| 86901 | 15 | 12 | $7.17 | |
| 86900 | 15 | 12 | $7.17 | |
| 81002 | 13 | 12 | $3.13 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 33 | 13 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 57 | 40 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 39 | 14 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 51 | 26 | $0.00 |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | 28 | 12 | $0.00 |